Completed PHASE3 INTERVENTIONAL NCT00246922

Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)

A Long-term Study of APTA-2217 in Adult Patients With Bronchial Asthma

Sponsor: AstraZeneca

Interventions Roflumilast

Updated 8 times since 2017 Last updated: Feb 16, 2026 Started: Dec 1, 2004 Primary completion: Jan 1, 2007 Completion: Oct 1, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bronchial Asthma, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 8 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Jan 2026 — Feb 2026 [monthly]

Completed PHASE3
Sep 2024 — Jan 2026 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Tanabe Pharma Corporation

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Osaka, Japan